Core Viewpoint - The company, Tianyu Biotechnology Co., Ltd., has initiated a lawsuit to exercise its shareholder rights and obtain financial information from the target company, Qinghai Juzhiyuan New Materials Co., Ltd., in order to accurately calculate the cash compensation owed by Liu Bingsheng for unmet performance commitments [2][12]. Group 1: Background of the Lawsuit - On March 28, 2022, the company signed a strategic investment agreement with Qinghai Juzhiyuan and Liu Bingsheng, investing 210 million RMB for a 35% stake, with a performance commitment of 900 million RMB in net profit over three years [3][11]. - The agreement includes provisions for cash compensation if the performance commitments are not met, allowing the company to either repurchase shares or receive cash compensation for any shortfall [3][11]. Group 2: Progress of Compensation Recovery - In August 2023, the company filed for arbitration due to Qinghai Juzhiyuan's 2022 net profit loss and Liu Bingsheng's failure to fulfill compensation obligations, resulting in an arbitration ruling in June 2025 that ordered Liu Bingsheng to pay 43.2953 million RMB in cash compensation [4][5]. - The company has applied for enforcement of this ruling in July 2025, but the execution status remains uncertain as it is still under court review [4][5]. Group 3: Current Lawsuit Details - The lawsuit was filed in July 2025 at the Qinghai Delingha People's Court, with the company requesting access to financial reports and accounting records from 2022 to 2024 to verify the performance commitments [9][10]. - The company asserts its right to access these documents as a shareholder, emphasizing that the refusal to provide such information has severely harmed its legal rights [11]. Group 4: Impact on Financials - The impact of the lawsuit on the company's current or future profits remains uncertain as the case has not yet been heard in court [2][12]. - The company is committed to monitoring the lawsuit closely and will disclose updates as necessary to protect the interests of itself and its shareholders [12].

每经记者｜程雅 每经编辑｜魏官红 7月29日晚，天域生物（SH603717，股价7.66元，市值22.23亿元）披露，近期，公司向青海省海西蒙古 族藏族自治州中级人民法院申请依法强制执行刘炳生向公司支付一次性现金补偿款及已预缴仲裁费。 2022年3月，天域生物与青海聚之源新材料有限公司（以下简称"聚之源"）、刘炳生签订《股权战略投 资协议》，以货币资金2.1亿元增资聚之源并获得35%的股权。 但由于对方未完成业绩承诺且未能提供有效的财务凭证，天域生物向上海仲裁委员会提起仲裁。不过， 仲裁结束后，对方仍未支付业绩补偿款，因此天域生物向法院申请强制执行。 交易对方未能完成三年业绩承诺 不过，2022年3月，天域生物更改了上述投资计划，新交易方案为公司通过增资的形式向聚之源投资2.1 亿元，以获得其35%股权。 之后，根据聚之源提供的2022年至2024年未经审计合并财务报表，其报告期内实现归母净利润分别 为-1.24亿元、-1亿元、-8676.33万元，三年累计实现金额为-3.11亿元，未能实现三年累计业绩承诺。 根据《股权投资协议》约定的业绩补偿计算方式，刘炳生应向天域生物支付补偿金额4.24亿元。 据悉，聚之 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次诉讼的背景 证券代码：603717 证券简称：天域生物 公告编号：2025-054 天域生物科技股份有限公司 关于公司提起诉讼的公告 （一）投资情况及业绩承诺、补偿约定 2022 年 03 月 28 日，天域生物科技股份有限公司（以下简称"公司"）与青 海聚之源新材料有限公司（以下简称"聚之源"或"标的公司"）、刘炳生先生 签订《股权战略投资协议》（以下简称"《股权投资协议》"），公司以货币资 金 2.1 亿元增资聚之源获得 35%的股权。聚之源及刘炳生承诺：标的公司在 2022 年度、2023 年度和 2024 年度承诺经审计的累计扣除非经常性损益后归属于母公 司（合并报表，下同）的净利润为人民币 9 亿元，净利润考核按三年总数计算； 1 案件所处的诉讼阶段：已立案受理，尚未开庭审理 上市公司所处的当事人地位：原告 涉案的金额：暂无 是否会对上市公司损益产生负面影响：由于本案尚未开庭审理，对本期 利润或期后利润的影响存在不确定性。本次诉讼旨在通过法律途径 ...

累计担保情况 | 对外担保逾期的累计金额（万元） | / | | --- | --- | | 截至本公告日上市公司及其控股子 | | | 公司对外担保总额（万元） | 112,133.65 | | （实际发生的担保余额，不含本次） | | | 对外担保总额占上市公司最近一期 | 216.17 | | 经审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | 对外担保总额超过最近一期经审计净资 | | 产 | 100% | | | □担保金额超过上市公司最近一期经审计 | | | 净资产 50% | | | □对合并报表外单位担保金额达到或超过 | | | 最近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | 一、担保情况概述 证券代码：603717 证券简称：天域生物 公告编号：2025-053 天域生物科技股份有限公司 关于公司 2025 年度对外担保预计的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 ...

上海市锦天城律师事务所 关于天域生物科技股份有限公司 2025年第二次临时股东大会的 法律意见书 锦 天 域 律师事务 所 ALLBRIGHT LAW OFFICES 地址:上海市浦东新区银城中路 501 号上海中心 11、12 层 电话: 021-20511000 传真: 021-20511999 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于天域生物科技股份有限公司 2025年第二次临时股东大会的法律意见书 致:天域生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受天域生物科技股份有限 公司(以下简称"公司")委托,就公司召开 2025年第二次临时股东大会(以 下简称"本次股东大会")的有关事宜,根据《中华人民共和国公司法》(以下 简称"《公司法》")《上市公司股东会规则》等法律、法规和其他规范性文件 以及《天域生物科技股份有限公司章程》(以下简称"《公司章程》")的有关 规定,出具本法律意见书。 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责, ...

证券代码：603717 证券简称：天域生物 公告编号：2025-052 天域生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 16 日 (二)股东大会召开的地点：上海市杨浦区国权北路 1688 号湾谷科技园 C4 幢二层 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 召开和表决符合《公司法》及《公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 | 1、出席会议的股东和代理人人数 | 168 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,770,880 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 0.8043 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董 ...

卫星化学：上半年净利润预增31.32%-53.20% 7月15日晚，卫星化学（002648）发布2025年半年度业绩预告，公司预计上半年实现归属于上市公司股 东的净利润27亿元至31.5亿元，同比增长31.32%-53.20%；预计实现扣除非经常性损益后的净利润28.52 亿元至33.02亿元，同比增长27.65%-47.79%。 资料显示，卫星化学成立于2005年8月，主营业务是(聚)丙烯、丙烯酸及酯、乙二醇、环氧乙烷、环氧 丙烷和聚乙烯等产品的生产和销售。 所属行业：基础化工–化学原料–其他化学原料 中国核建：累计新签合同871.49亿元 7月15日晚，中国核建（601611）发布公告称，截至2025年6月，公司累计实现新签合同871.49亿元，累 计实现营业收入531.84亿元。 资料显示，中国核建成立于2010年12月，主营业务是核电工程建设及工业与民用工程建设。 所属行业：建筑装饰–基础建设–基建市政工程 资料显示，怡球资源成立于2001年3月，主营业务是利用所回收的各种废旧铝资源，进行分选、加工、 熔炼等工序，生产出再生铝合金产品。 所属行业：有色金属–工业金属–铝 光库科技：上半年净利润预增60 ...

Group 1 - The company expects a net profit attributable to shareholders of 8 million to 12 million yuan for the first half of 2025, representing an increase of 177.14 thousand to 577.14 thousand yuan compared to the same period last year, with a year-on-year growth of 28.44% to 92.66% [2][3] - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -18 million and -12 million yuan, which is a decrease of 893.04 thousand to 1,493.04 thousand yuan compared to the same period last year [2][3] - The total sales revenue is projected to be 311.53 million yuan, an increase of 17.49% compared to the same period last year, driven by stable improvements in pig farming operations [2][3] Group 2 - The company reported a total profit of 14.74 million yuan and a net profit attributable to shareholders of 6.23 million yuan for the same period last year [2] - The earnings per share for the previous year was 0.0215 yuan [2] - The increase in asset disposal income is attributed to renegotiations regarding rent reductions and pig farm renovations [2]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates H1 2025 net profit attributable to shareholders to range from RMB 8 million to RMB 12 million, while net profit after non-recurring items is expected to be a loss of RMB 12 million to RMB 18 million, indicating an expanded loss H1 2025 Performance Forecast Summary | Indicator | H1 2025 Forecast | Prior Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | RMB 8 million to RMB 12 million | RMB 6.2286 million | +28.44% to +92.66% | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | RMB -18 million to RMB -12 million | RMB -3.0696 million | Loss increased by RMB 8.9304 million to RMB 14.9304 million | - This performance forecast represents preliminary calculations by the company's finance department and has not been audited by a certified public accountant[6](index=6&type=chunk) [Review of Prior Period Performance](index=2&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) In H1 2024, the company reported net profit attributable to shareholders of RMB 6.2286 million, with a net loss of RMB 3.0696 million after non-recurring items, and basic EPS of RMB 0.0215 H1 2024 Key Financial Indicators | Indicator | H1 2024 Data | | :--- | :--- | | Total Profit | RMB 14.7447 million | | Net Profit Attributable to Parent Company Shareholders | RMB 6.2286 million | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | RMB -3.0696 million | | Earnings Per Share | RMB 0.0215 | [Analysis of Performance Change Reasons](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%A2%9E%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The projected increase in net profit attributable to shareholders is primarily due to stable growth in hog sales and a one-time asset disposal gain, while the expanded loss in net profit after non-recurring items is mainly attributed to reduced interest income - Stable improvement in the operating performance of the hog farming business is a primary driver of net profit growth[9](index=9&type=chunk) Hog Sales Business Performance | Hog Sales Business | H1 2025 Data | Year-on-Year Growth | | :--- | :--- | :--- | | Sales Volume | **204,200 heads** | +21.52% | | Sales Revenue | **RMB 311.5323 million** | +17.49% | - Renegotiation of the pig farm lease contract in Caidian District, Wuhan City, resulted in reduced rent and rent exemption during the renovation period, which is expected to increase the company's asset disposal gains[9](index=9&type=chunk) - The increased loss in net profit after non-recurring items is primarily due to a decrease in interest income during the reporting period[9](index=9&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company emphasizes that this unaudited performance forecast is a preliminary calculation, and investors should refer to the officially disclosed 2025 semi-annual report for final accurate financial data - The company states that this performance forecast is preliminary and unaudited, advising investors to be aware of investment risks and rely on the final semi-annual report for definitive data[10](index=10&type=chunk)[11](index=11&type=chunk)

天域生物（603717）公告，预计2025年半年度实现归属于母公司所有者的净利润800万元到1200万元， 与上年同期相比，将增加177.14万元到577.14万元，同比增加28.44%到92.66%。 ...